🇺🇸 FDA
Patent

US 8247555

Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

granted A61KA61K31/46A61K31/485

Quick answer

US patent 8247555 (Crystalline forms of an 8-azabicyclo[3.2.1]octane compound) held by Theravance, Inc. expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/46, A61K31/485, A61K45/06, A61P